Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...

Merck MRK along with partner Eisai announced data from the phase III LEAP-015 study, which evaluated blockbuster PD-1 ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Innovent Biologics, ASK Pharm announce China’s NMPA approval of limertinib to treat metastatic EGFR T790M-mutated NSCLCr: San Francisco Saturday, January 18, 2025, 09:00 Hrs [IS ...

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company with a market capitalization of $5.4 billion, has been gaining attention in the biotechnology sector for its innovative ...

The safety profile aligned with other EGFR-targeting agents in its class ... Limertinib is an orally-administrated, third-generation EGFR TKI with proprietary rights, approved by the China's NMPA for ...

Limertinib is the 14th product in Innovent's commercial portfolio and represents a cutting-edge addition to its strong TKI franchise ... robust efficacy and safety profile. Independent review ...

The safety profile aligned with other EGFR-targeting ... Limertinib is an orally-administrated, third-generation EGFR TKI with proprietary rights, approved by the China's NMPA for the treatment ...